Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences
US-based small molecule medicines provider Innoviva (formerly Advanced Medicine) has announced a private placement of convertible senior notes due 2025 to raise $175m.
Biotechnology company Seattle Genetics plans to acquire biopharmaceutical firm Bristol-Myers Squibb’s pharmaceutical manufacturing facility located in Bothell, Washington, US.
The acquisition will help the company to expand its antibody drug conjugate and immuno-oncology pipeline.
PlasmaGen BioSciences Private has secured $25m through a venture financing round led by Eight Roads Ventures India.
The Indian biopharmaceutical company will use the funds for the expansion of its product portfolio.